DB2313,2170606-74-1

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

DB2313

CAS No. : 2170606-74-1

MCE 国际站：DB2313

产品活性：DB2313 是一种有效的转录因子 PU.1 抑制剂，apoptosis 为 14 nM。DB2313 破坏了 PU.1 与靶基因启动子的相互作用。DB2313 可诱导急性髓细胞性白血病 (AML) 细胞凋亡 (apoptosis)，并具有抗癌作用。

研究领域：Apoptosis

作用靶点：Apoptosis

In Vitro: DB2313 treatment leads to a profound decrease in the growth of PU.1 URE^–/– acute myeloid leukemia (AML) cells (IC₅₀ of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE^–/– AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating.
In AML cells, DB2313 decreases PU.1 occupancy on E2f1, Junb, and Csf1r promoters.

In Vivo: DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice.

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Anti-Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Cell Death Library  |  MG-132  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  LY294002  |  Tamoxifen  |  Paclitaxel  |  Y-27632  |  Acetylcysteine  |  Angiotensin II human  |  2-Deoxy-D-glucose  |  Staurosporine  |  SB-431542  |  Actinomycin D  |  Deferoxamine mesylate  |  Bortezomib  |  5-Fluorouracil  |  Trametinib  |  Sorafenib  |  Oxaliplatin  |  Gemcitabine  |  Temozolomide  |  Rotenone  |  Mdivi-1  |  Elesclomol  |  Ruxolitinib  |  Decitabine  |  SP600125  |  MK-2206 dihydrochloride  |  Etoposide  |  Monomethyl auristatin E

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds